inVentiv Health, Inc. announced unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009. Total revenues decreased 6% to $270.5 million for the third quarter of 2009, compared to $289.2 million for the third quarter of 2008. Adjusted EBITDA decreased 12% to $32.6 million for the third quarter of 2009, compared to $37.2 million for the third quarter of 2008. Adjusted operating income decreased 13% to $24.3 million for the third quarter of 2009, compared to $27.8 million for the third quarter of 2008. GAAP operating income was $24.6 million for the third quarter of 2009, compared to $27.6 million for the third quarter of 2008. Adjusted Net income attributable to inVentiv Health, Inc. was $11.5 million for the third quarter of 2009, compared to adjusted net income of $13.6 million for the third quarter of 2008. Net income attributable to inVentiv Health, Inc., was $11.7 million for the third quarter of 2009, compared to $13.3 million for the third quarter of 2008. Adjusted diluted earnings per share (EPS) attributable to inVentiv Health, Inc. was $0.34 for the third quarter of 2009 and GAAP diluted EPS was $0.35, compared to an adjusted diluted EPS of $0.41 for the third quarter of 2008 and GAAP diluted EPS of $0.40 for the third quarter of 2008. The company also generated $20.9 million of cash flow from continuing operations for the quarter. Income from continuing operations of $11.8 million or $0.35 per diluted share compared to income from continuing operations of $13.4 million or $0.40 per diluted share for the same period of last year. For the nine months, the company reported income from continuing operations of $31.0 million or $0.92 per diluted share compared to income from continuing operations of $35.4 million or $1.03 per diluted share for the same period of last year. The company reported operating income of $68.7 million and net income attributable to the company of $30.9 million or $0.92 per diluted share on total revenues of $797.1 million compared to operating income of $75.4 million and net income attributable to the company of $34.5 million or $1.03 per diluted share on total revenues of $836.5 million for the same period of last year. The company also generated $78.7 million of cash flow from continuing operations for nine months of 2009. The company is providing a fourth quarter 2009 revenue target range of $270 million to $285 million and earnings per share target range of $0.40 to $0.43. The company announced that Terry Herring, president and chief operating officer will resign his position effective December 31, 2009.

Star Scientific, Inc. announced that the company plans to introduce the CigRx(TM) nutraceutical product developed by its subsidiary, Rock Creek Pharmaceuticals, for worldwide marketing and sales in partnership with inVentiv Health, Inc. inVentiv Health offers a complete range of commercialization solutions for every stage of the product lifecycle, in a range of healthcare categories that includes nutraceutical products. The company has marketing and sales capabilities in 40 countries around the globe.

inVentiv Health, Inc. - Conference Presentation Calls